
    
      DUS1 will be conducted when the target number of new users of aclidinium monotherapy is
      reached, and DUS2 when the target number of new users of aclidinium fixed-dose combination
      with formoterol is reached.

      As this was a descriptive study no primary or secondary endpoints were specified.
    
  